ROCCI, LAURA
ROCCI, LAURA
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients
2007-01-01 Santini, D; Virzi, V; Vincenzi, B; Rocci, L; Leoni, V; Tonini, G
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients
2006-01-01 Vincenzi, B; Santini, D; Russo, A; Silletta, M; Gavasci, M; Battistoni, F; Di Cuonzo, G; Rocci, L; Gebbia, N; Tonini, G
Bisphosphonates: new antiangiogenic molecules in cancer treatment?
2003-01-01 Vincenzi, B; Santini, D; Rocci, L; Tonini, G
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan
2007-01-01 Vincenzi, B; Santini, D; Russo, A; Gavasci, M; Battistoni, F; Dicuonzo, G; Rocci, L; Rosaria, Vm; Gebbia, N; Tonini, G
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients
2005-01-01 Santini, D; Vincenzi, B; LA CESA, A; Caricato, M; Schiavon, G; Spalletta, B; DI SERI, M; Coppola, R; Rocci, L; Tonini, G.
Docetaxel induced pericardial effusion
2007-01-01 Vincenzi, B; Santini, D; Frezza, Am; Rocci, L; Tonini, G
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
2011-01-01 Vincenzi, B; Galluzzo, S; Santini, D; Rocci, L; Loupakis, F; Correale, P; Addeo, R; Zoccoli, A; Napolitano, A; Graziano, F; Ruzzo, A; Falcone, A; Francini, G; Dicuonzo, G; Tonini, G
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome
2008-01-01 Vincenzi, B; Santini, D; Galluzzo, S; Russo, A; Fulfaro, F; Silletta, M; Battistoni, F; Rocci, L; Beomonte Zobel, B; Adamo, V; Dicuonzo, G; Tonini, G
Fatal thrombocytopenia and thrombocytopathia: An unusual onset of non small cell lung cancer
2003-01-01 Tonini, G; Vincenzi, B; Di Cosimo, S; Gravante, G; Santini, D; Ambrogi, V; Micheletti, E; Rocci, L; D'Aprile, M
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6
2003-01-01 Dicuonzo, G; Vincenzi, B; Santini, D; Avvisati, G; Rocci, L; Battistoni, F; Gavasci, M; Borzomati, D; Coppola, R; Tonini, G
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients
2009-01-01 Santini, D; Martini, F; Fratto, Me; Galluzzo, S; Vincenzi, B; Agrati, C; Turchi, F; Piacentini, P; Rocci, L; Manavalan, Js; Tonini, G; Poccia, F
Meeting information needs on cancer-related fatigue: an exploration of views held by Italian patients and nurses
2007-01-01 Piredda, M; De Marinis, M; Rocci, L; Gualandi, R; Tartaglini, D; Ream, E
Prospective observational multicentric case-control study about 'fatigue' in patients with history of breast cancer
2005-01-01 Gualandi, Raffaella; Santini, Daniele; Fabi, Alessandra; Romiti, Adriana; Vincenzi, Bruno; Rocci, Laura; Massacesi, Cristian; Cognetti, Francesco; Tonini, Giuseppe
Repeated intermittent low-dose therapy with zoledronic Acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients
2007-01-01 Santini, D; Vincenzi, B; Galluzzo, S; Battistoni, F; Rocci, L; Venditti, O; Schiavon, G; Angeletti, S; Uzzalli, F; Caraglia, M; Dicuonzo, G; Tonini, G
S-Adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury
2003-01-01 Santini, D; Vincenzi, B; Massacesi, C; Picardi, A; Gentilucci, Uv; Esposito, V; Liuzzi, G; La Cesa, A; Rocci, L; Marcucci, F; Montesarchio, V; Groeger, Am; Bonsignori, M; Tonini, G; Baldi, A
Scientific Evidence for Non-Pharmacological Management of the Main Side-Effects of Antineoplastic Drugs in Colorectal Cancer Patients. [Evidenze scientifiche per la gestione non farmacologica dei principali effetti collaterali della terapia antineoplastica nei pazienti con cancro colon-rettale]
2009-01-01 Gualandi, R; Piredda, M; Rocci, L; De Benedictis, A; Matarese, M; Tartaglini, D; DE MARINIS, MARIA GRAZIA
Survey on learning needs and preferred sources of information to meet these needs in Italian oncology patients receiving chemotherapy
2008-01-01 Piredda, M; Rocci, L; Gualandi, R; Petitti, T; Vincenzi, B; DE MARINIS, MARIA GRAZIA
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
2003-01-01 Santini, D; Vincenzi, B; Dicuonzo, G; Avvisati, G; Massacesi, C; Battistoni, F; Gavasci, M; Rocci, L; Tirindelli, Mc; Altomare, V; Tocchini, M; Bonsignori, M; Tonini, G
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
2005-01-01 Vincenzi, B; Santini, D; Dicuonzo, G; Battistoni, F; Gavasci, M; La Cesa, A; Grilli, C; Virzi, V; Gasparro, S; Rocci, L; Tonini, G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients | 1-gen-2007 | Santini, D; Virzi, V; Vincenzi, B; Rocci, L; Leoni, V; Tonini, G | |
| Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients | 1-gen-2006 | Vincenzi, B; Santini, D; Russo, A; Silletta, M; Gavasci, M; Battistoni, F; Di Cuonzo, G; Rocci, L; Gebbia, N; Tonini, G | |
| Bisphosphonates: new antiangiogenic molecules in cancer treatment? | 1-gen-2003 | Vincenzi, B; Santini, D; Rocci, L; Tonini, G | |
| Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan | 1-gen-2007 | Vincenzi, B; Santini, D; Russo, A; Gavasci, M; Battistoni, F; Dicuonzo, G; Rocci, L; Rosaria, Vm; Gebbia, N; Tonini, G | |
| Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients | 1-gen-2005 | Santini, D; Vincenzi, B; LA CESA, A; Caricato, M; Schiavon, G; Spalletta, B; DI SERI, M; Coppola, R; Rocci, L; Tonini, G. | |
| Docetaxel induced pericardial effusion | 1-gen-2007 | Vincenzi, B; Santini, D; Frezza, Am; Rocci, L; Tonini, G | |
| Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients | 1-gen-2011 | Vincenzi, B; Galluzzo, S; Santini, D; Rocci, L; Loupakis, F; Correale, P; Addeo, R; Zoccoli, A; Napolitano, A; Graziano, F; Ruzzo, A; Falcone, A; Francini, G; Dicuonzo, G; Tonini, G | |
| Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome | 1-gen-2008 | Vincenzi, B; Santini, D; Galluzzo, S; Russo, A; Fulfaro, F; Silletta, M; Battistoni, F; Rocci, L; Beomonte Zobel, B; Adamo, V; Dicuonzo, G; Tonini, G | |
| Fatal thrombocytopenia and thrombocytopathia: An unusual onset of non small cell lung cancer | 1-gen-2003 | Tonini, G; Vincenzi, B; Di Cosimo, S; Gravante, G; Santini, D; Ambrogi, V; Micheletti, E; Rocci, L; D'Aprile, M | |
| Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 | 1-gen-2003 | Dicuonzo, G; Vincenzi, B; Santini, D; Avvisati, G; Rocci, L; Battistoni, F; Gavasci, M; Borzomati, D; Coppola, R; Tonini, G | |
| In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients | 1-gen-2009 | Santini, D; Martini, F; Fratto, Me; Galluzzo, S; Vincenzi, B; Agrati, C; Turchi, F; Piacentini, P; Rocci, L; Manavalan, Js; Tonini, G; Poccia, F | |
| Meeting information needs on cancer-related fatigue: an exploration of views held by Italian patients and nurses | 1-gen-2007 | Piredda, M; De Marinis, M; Rocci, L; Gualandi, R; Tartaglini, D; Ream, E | |
| Prospective observational multicentric case-control study about 'fatigue' in patients with history of breast cancer | 1-gen-2005 | Gualandi, Raffaella; Santini, Daniele; Fabi, Alessandra; Romiti, Adriana; Vincenzi, Bruno; Rocci, Laura; Massacesi, Cristian; Cognetti, Francesco; Tonini, Giuseppe | |
| Repeated intermittent low-dose therapy with zoledronic Acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients | 1-gen-2007 | Santini, D; Vincenzi, B; Galluzzo, S; Battistoni, F; Rocci, L; Venditti, O; Schiavon, G; Angeletti, S; Uzzalli, F; Caraglia, M; Dicuonzo, G; Tonini, G | |
| S-Adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury | 1-gen-2003 | Santini, D; Vincenzi, B; Massacesi, C; Picardi, A; Gentilucci, Uv; Esposito, V; Liuzzi, G; La Cesa, A; Rocci, L; Marcucci, F; Montesarchio, V; Groeger, Am; Bonsignori, M; Tonini, G; Baldi, A | |
| Scientific Evidence for Non-Pharmacological Management of the Main Side-Effects of Antineoplastic Drugs in Colorectal Cancer Patients. [Evidenze scientifiche per la gestione non farmacologica dei principali effetti collaterali della terapia antineoplastica nei pazienti con cancro colon-rettale] | 1-gen-2009 | Gualandi, R; Piredda, M; Rocci, L; De Benedictis, A; Matarese, M; Tartaglini, D; DE MARINIS, MARIA GRAZIA | |
| Survey on learning needs and preferred sources of information to meet these needs in Italian oncology patients receiving chemotherapy | 1-gen-2008 | Piredda, M; Rocci, L; Gualandi, R; Petitti, T; Vincenzi, B; DE MARINIS, MARIA GRAZIA | |
| Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients | 1-gen-2003 | Santini, D; Vincenzi, B; Dicuonzo, G; Avvisati, G; Massacesi, C; Battistoni, F; Gavasci, M; Rocci, L; Tirindelli, Mc; Altomare, V; Tocchini, M; Bonsignori, M; Tonini, G | |
| Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients | 1-gen-2005 | Vincenzi, B; Santini, D; Dicuonzo, G; Battistoni, F; Gavasci, M; La Cesa, A; Grilli, C; Virzi, V; Gasparro, S; Rocci, L; Tonini, G |